Category: 62937-45-5

62937-45-5,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.

A solution of N(4-(5-(difluoromethyl)- 1,3 ,4-oxadiazol-2-yl)benzyl)-N-phenylethenesulfonamide(0.100 g, 0.255 mmol), D-(-)-prolinamide (0.058 g, 0.5 11 mmol) and N,N-diisopropylethylamine (0.176 mL, 1.022 mmol) in dichloromethane (5 mL) was stilTed at the room temperature for 18 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Waters, Cl 8; acetonitrile / aqueous 0.1%-formic acid solution = 10 % to 90 %) to give (R)- 1 -(2-(N-(4-(5-(difluoromethyl)- 1,3 ,4-oxadiazol-2-yl)benzyl)-N-phenylsulfamoyl)e thyl)pyffolidine-2-carboxamide as white solid (0.120 g, 92.9 %).?H NMR (400 MHz, DMSO-d6) oe 7.96( d, 2 H,J = 8.4 Hz), 7.50 (d, 2 H, J = 8.3 Hz), 7.43 -7.22 (m, 6 H), 7.11 (br, 2 H), 5.00 (s, 2 H), 4.02 (q, 1 H, J= 5.2 Hz), 3.47 (m, 2 H), 3.32 (s, 1 H), 3.15 – 3.13 (m, 1 H), 2.94 – 2.81 (m, 2 H), 2.34 – 2.30 (m, 1 H), 2.06 (m, 1 H), 1.74 – 1.69 (m, 2 H); LRMS (ES) mlz 506.1 (M+1).

As the paragraph descriping shows that 62937-45-5 is playing an increasingly important role.

Reference£º
Patent; CHONG KUN DANG PHARMACEUTICAL CORP.; LEE, Jaekwang; HAN, Younghue; KIM, Yuntae; CHOI, Daekyu; MIN, Jaeki; BAE, Miseon; YANG, Hyunmo; KIM, Dohoon; (644 pag.)WO2017/18803; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.,62937-45-5

A stirred suspension of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-Methyl-2-pyrrolidinone (1 mL) was subjected to microwave irradiation at 150 C for 2 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2 x 20 mL), dried, filtered and concentrated in vacuum. The crude residue was purified by combiflash (silica gel, 12 g, eluting with chloroform/CMA-80) to afford (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34 % yield) as a light yellow solid; NMR (300 MHz, DMSO-i) delta 9.90 (s, 1H, D20 exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83 – 3.69 (m, 1H), 3.64 (s, 3H), 3.62 – 3.49 (m, 1H), 3.48 – 3.23 (m, 2H), 2.07 – 1.83 (m, 4H); MS (ES+): 315.4 (M+l), 337.5 (M+Na), (ES-): 313.4 (M- 1). HPLC purity: 98.70%.

The synthetic route of 62937-45-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BIOCRYST PHARMACEUTICALS, INC.; KOTIAN, Pravin, L.; BABU, Yarlagadda, S.; KUMAR, V., Satish; ZHANG, Weihe; LU, Peng-Cheng; RAMAN, Krishnan; (747 pag.)WO2018/232094; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.,62937-45-5

General procedure: A stirred suspension of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-Methyl-2-pyrrolidinone (1 mL) was subjected to microwave irradiation at 150 C for 2 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2 x 20 mL), dried, filtered and concentrated in vacuum. The crude residue was purified by combiflash (silica gel, 12 g, eluting with chloroform/CMA-80) to afford (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34 % yield) as a light yellow solid; NMR (300 MHz, DMSO-i) delta 9.90 (s, 1H, D20 exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83 – 3.69 (m, 1H), 3.64 (s, 3H), 3.62 – 3.49 (m, 1H), 3.48 – 3.23 (m, 2H), 2.07 – 1.83 (m, 4H); MS (ES+): 315.4 (M+l), 337.5 (M+Na), (ES-): 313.4 (M- 1). HPLC purity: 98.70%.

62937-45-5 D-Prolinamide 447554, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BIOCRYST PHARMACEUTICALS, INC.; KOTIAN, Pravin, L.; BABU, Yarlagadda, S.; KUMAR, V., Satish; ZHANG, Weihe; LU, Peng-Cheng; RAMAN, Krishnan; (747 pag.)WO2018/232094; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

62937-45-5, A solution of 5-(4-chlorophenyl)-2-{ [l-(2-chloropyridin-3-yl) H-l,2,4-triazol-3-yl]methyl}-4- [(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-l,2,4-triazol-3-one (Example 44A; 70.0 mg, 140 muiotaetaomicron) in ethanol (280 mu) was treated with D-prolinamide (160 mg, 1.40 mmol) and stirred overnight at reflux. The reaction mixture was diluted with methanol and purified by preparative HPLC (Method 4) affording 56.3 mg (70 % of th.) of the title compound. LC-MS (Method 2): Rt = 1.52 min; MS (ESIpos): m/z = 578.2 [M+H]+ -NMR (400 MHz, DMSO-d6) delta [ppm]: 8.80 (s, 1H), 8.19 (dd, 1H), 7.79-7.52 (m, 5H), 7.06 (br s, 1H), 6.95-6.71 (m, 3H), 5.18-5.02 (m, 2H), 4.48-4.21 (m, 2H), 4.06-3.78 (m, 2H), 2.77-2.58 (m, 2H), 2.04-1.87 (m, 1H), 1.75-1.42 (m, 3H).

62937-45-5 D-Prolinamide 447554, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGESELLSCHAFT; COLLIN-KROePELIN, Marie-Pierre; KOLKHOF, Peter; NEUBAUER, Thomas; FUeRSTNER, Chantal; POOK, Elisabeth; WITTWER, Matthias, Beat; LUSTIG, Klemens; TINEL, Hanna; LINDNER, Niels; SCHIRMER, Heiko; (449 pag.)WO2019/81307; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5,62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

D-Prolinamide (42.8 mg, 375 muiotaetaomicron) and N,N-diisopropylethylamine (65 mu, 380 mumol) were added to a solution of 2-[3-({3-(4-chlorophenyl)-5-oxo-4-[(2S)-3,3,3-trifluoro-2-hydroxypropyl]-4,5- dihydro-lH-l,2,4-triazol-l-yl}methyl)-lH-l,2,4-triazol-l-yl]benzoyl chloride (Example 58A, 79.1 mg, 150 muiotaetaomicron) in tetrahydrofuran (2.3 ml). This reaction mixture was stirred for 1 h at room temperature. The crude product was purified by preparative HPLC (Method 4). Lyophihsation of the product containing fractions afforded 53.9 mg (57 % of th.) of the title compound. LC-MS (Method 2): Rt = 1.53 min; MS (ESIpos): m/z = 605 [M+H]+ -NMR (400 MHz, DMSO-d6) delta [ppm]: -0.215 (1.05), -0.008 (3.93), 0.008 (3.02), 0.716 (3.19), 1.701 (2.80), 1.716 (2.72), 1.742 (2.33), 1.759 (3.07), 1.776 (3.57), 1.787 (3.15), 1.798 (2.94), 1.812 (1.93), 2.053 (1.59), 2.073 (1.94), 2.709 (0.57), 3.205 (1.74), 3.231 (1.37), 3.247 (2.09), 3.287 (4.72), 3.373 (0.82), 3.441 (1.05), 3.816 (1.83), 3.824 (1.18), 3.840 (2.10), 3.852 (2.94), 3.860 (1.87), 3.877 (2.98), 3.884 (2.00), 3.974 (4.06), 3.982 (4.47), 4.010 (2.84), 4.019 (2.68), 4.217 (1.80), 4.229 (1.82), 4.309 (2.20), 5.021 (1.30), 5.061 (14.55), 5.069 (10.76), 5.109 (1.19), 6.913 (3.15), 6.928 (5.00), 6.958 (4.94), 6.973 (4.86), 7.064 (3.77), 7.297 (2.31), 7.342 (3.89), 7.411 (1.12), 7.472 (1.37), 7.492 (2.44), 7.509 (1.27), 7.539 (1.39), 7.556 (3.82), 7.577 (3.93), 7.601 (12.46), 7.614 (6.91), 7.617 (8.60), 7.622 (16.00), 7.629 (8.66), 7.635 (11.09), 7.648 (3.33), 7.676 (3.24), 7.696 (2.26), 7.723 (5.02), 7.745 (10.67), 7.752 (12.89), 7.767 (6.68), 7.773 (9.27), 8.933 (10.76).

As the paragraph descriping shows that 62937-45-5 is playing an increasingly important role.

Reference£º
Patent; BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGESELLSCHAFT; COLLIN-KROePELIN, Marie-Pierre; KOLKHOF, Peter; NEUBAUER, Thomas; FUeRSTNER, Chantal; POOK, Elisabeth; WITTWER, Matthias, Beat; LUSTIG, Klemens; TINEL, Hanna; LINDNER, Niels; SCHIRMER, Heiko; (449 pag.)WO2019/81307; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI